In a groundbreaking move for women’s health, the widely recognised condition known as polycystic ovary syndrome (PCOS) has officially been renamed polyendocrine metabolic ovarian syndrome (PMOS). This change, announced at the European Congress of Endocrinology in Prague and published in *The Lancet*, aims to provide clarity and hope for the estimated 170 million women worldwide affected by this complex hormonal disorder. The transition comes after over a decade of advocacy led by patients and medical professionals alike, highlighting the urgent need to improve understanding and treatment of this condition.
The Journey to Renaming
The renaming of PCOS to PMOS stems from decades of patient advocacy and research into the condition’s true nature. Historically, the term “polycystic” has led to significant misunderstandings, often resulting in delayed diagnoses and inadequate care. As Professor Helena Teede, director of Melbourne’s Monash Centre for Health Research & Implementation, explains, the name change reflects the multifaceted impacts of the condition, which extends beyond the reproductive system to include metabolic health and increased risks of diabetes and cardiovascular issues.
Maddy Mavrikis, a resident of Sydney and one of the many women who shared her experiences with the Guardian, recalled her own diagnosis at age 15. She was told she might struggle to conceive, a notion that proved unfounded. Mavrikis’s experience underscores the confusion that comes with the old nomenclature, especially since she never exhibited the classic “polycystic ovaries” on ultrasound.
Understanding PMOS
The symptoms of PMOS can manifest in various ways, including irregular menstrual cycles, high androgen levels, and insulin resistance, all of which can lead to health complications if left unaddressed. The condition affects an estimated one in eight women, yet many remain unaware of its broader implications. For Mavrikis, the realisation that her diagnosis didn’t correspond with the name she was given was a significant hurdle in her health journey.
The rebranding to PMOS not only aims to rectify misconceptions but also to encourage a more holistic approach to treatment. Teede emphasises that focusing on the endocrine aspects of the condition will help dispel myths and enable healthcare providers to offer more comprehensive care.
The Role of Patient Advocacy
The movement for renaming PCOS was largely driven by patients who felt that their experiences were being overlooked. Lorna Berry, a long-time advocate for better education around the condition, was pivotal in the discussions leading to the name change. She highlighted the importance of including patient voices in medical decision-making, stating that it is crucial for healthcare providers to recognise patients as equal partners in their care.
The name change has been in the making for years, with discussions and proposals surfacing as early as 1995. The collaborative effort involved 56 medical and patient societies from various global regions, ensuring that the new terminology resonates on a worldwide scale. This unprecedented level of cooperation aims to foster a deeper understanding of PMOS and its implications, which can vary widely among individuals.
A New Hope for the Future
As the medical community prepares to implement this name change into international guidelines by 2028, many women express cautious optimism. Mavrikis, echoing sentiments shared by countless others, sees the renaming as a beacon of hope for improved recognition and treatment of PMOS. She believes that with greater awareness, medical professionals will be more inclined to address the full spectrum of symptoms and seek preventive measures rather than solely focusing on fertility.
The frustrations experienced by women like Mavrikis and others, who have navigated a healthcare system that often dismisses their concerns, highlight the critical need for reform in how PMOS is understood and managed.
Why it Matters
This renaming signifies not just a shift in terminology but a transformative moment in how we approach women’s health issues globally. By acknowledging the complexities of PMOS, the medical community is taking a crucial step towards dismantling long-standing barriers that have hindered effective treatment. Recognising patient experiences as integral to the conversation about health conditions can lead to more informed, sensitive, and comprehensive care. As awareness of PMOS spreads, we may finally see a future where women receive the support and understanding they deserve, paving the way for improved health outcomes for millions.
